Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial

INTRODUCTION: ACTG A5288 was a strategy trial conducted in diverse populations from multiple continents of people living with HIV (PLWH) failing second‐line protease inhibitor (PI)‐based antiretroviral therapy (ART) from 10 low‐ and middle‐income countries (LMICs). Participants resistant to lopinavi...

Descripción completa

Detalles Bibliográficos
Autores principales: Avihingsanon, Anchalee, Hughes, Michael D., Salata, Robert, Godfrey, Catherine, McCarthy, Caitlyn, Mugyenyi, Peter, Hogg, Evelyn, Gross, Robert, Cardoso, Sandra W., Bukuru, Aggrey, Makanga, Mumbi, Badal‐aesen, Sharlaa, Mave, Vidya, Ndege, Beatrice Wangari, Fontain, Sandy Nerette, Samaneka, Wadzanai, Secours, Rode, Van Schalkwyk, Marije, Mngqibisa, Rosie, Mohapi, Lerato, Valencia, Javier, Sugandhavesa, Patcharaphan, Montalban, Esmelda, Munyanga, Cornelius, Chagomerana, Maganizo, Santos, Breno R., Kumarasamy, Nagalingeswaran, Kanyama, Cecilia, Schooley, Robert T., Mellors, John W., Wallis, Carole L., Collier, Ann C., Grinsztejn, Beatriz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332128/
https://www.ncbi.nlm.nih.gov/pubmed/36039892
http://dx.doi.org/10.1002/jia2.25905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332128/
https://www.ncbi.nlm.nih.gov/pubmed/36039892
http://dx.doi.org/10.1002/jia2.25905

Ejemplares similares